CORRECTION Open Access

Correction to: Low-chloride- versus high-chloride-containing hypertonic solution for the treatment of subarachnoid hemorrhage-related complications: The ACETatE (A low ChloriE hyperTonic solution for brain Edema) randomized trial



Ofer Sadan^{1*}, Kai Singbartl², Jacqueline Kraft¹, Joao McONeil Plancher¹, Alexander C. M. Greven³, Prem Kandiah¹, Cederic Pimentel¹, C. L. Hall¹, Alexander Papangelou⁴, William H. Asbury⁵, John J. Hanfelt⁶ and Owen Samuels¹

Correction to: J Intensive Care 8, 32 (2020) https://doi.org/10.1186/s40560-020-00449-0

Following the publication of the original article [1], it was noted that Fig. 3b had an erroneous graph. The correct Fig. 3 has been included in this correction. The authors apologize for this error.

Author details

¹Department of Neurology and Neurosurgery, Division of Neurocritical Care, Emory University Hospital and Emory University School of Medicine, 1364 Clifton Rd. NE, Atlanta, GA 30322, USA. ²Department of Critical Care Medicine, Mayo Clinic, 5777 E Mayo Blvd, Phoenix, AZ 85054, USA. ³School of Medicine, Emory University, 1364 Clifton Rd. NE, Atlanta, GA 30322, USA. ⁴Department of Anesthesiology, Emory University Hospital and Emory University School of Medicine, 1364 Clifton Rd. NE, Atlanta, GA 30322, USA. ⁵Department of Pharmacy, Emory University Hospital, 1364 Clifton Rd. NE, Atlanta, GA 30322, USA. ⁶Department of Biostatistics and Bioinformatics, Emory University, 1364 Clifton Rd. NE, Atlanta, GA 30322, USA.

Published online: 01 September 2020

Reference

 Sadan O, et al. Low-chloride- versus high-chloride-containing hypertonic solution for the treatment of subarachnoid hemorrhage-related complications: The ACETatE (A low ChloriE hyperTonic solution for brain Edema) randomized trial. J Intensive Care. 2020;8:32. https://doi.org/10. 1186/s40560-020-00449-0.

The original article can be found online at https://doi.org/10.1186/s40560-020-00449-0.

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

^{*} Correspondence: ofer.sadan@gmail.com

¹Department of Neurology and Neurosurgery, Division of Neurocritical Care, Emory University Hospital and Emory University School of Medicine, 1364 Clifton Rd. NE, Atlanta, GA 30322, USA

Sadan et al. Journal of Intensive Care (2020) 8:66 Page 2 of 2




Fig. 3 The effect of hypertonic solution on renal function and ICP reduction. **a** The rate of AKI was lower in the NaCl/Na-acetate group as compared with the NaCl group in an intention to treat analysis. **b** Comparison of Na $^+$ /Cl $^-$ loads with the study intervention doses, post-randomization. **c** Histogram of AKI frequency by group of treatment and hospitalization day. *p < 0.05. AKI, acute kidney injury; KDIGO, Kidney Disease: Improving Global Outcomes grading for AKI